International audienceA large fraction of the sequence variants of unknown significance or unclassified variants (UVs), including exonic variants, could be pathogenic by affecting mRNA splicing. The breast and ovarian cancer susceptibility gene BRCA1 exhibits a large spectrum of sequence variation but only two variants, both located in exon 18, have been shown experimentally to affect splicing regulatory elements. In the present study, we investigate the impact on splicing of the variant BRCA1 c.5434C>G (p.Pro1812Ala), identified in an ovarian cancer patient. This variant has previously been studied at the protein level with inconclusive results concerning its pathogenicity. Here, we show, using patient RNA analyses and hybrid minigene assa...
Screening for pathogenic mutations in breast and ovarian cancer genes such as BRCA1/2, CHEK2 and RAD...
A recent analysis using family history weighting and co-observation classification modeling indicate...
Screening for pathogenic mutations in breast and ovarian cancer genes such as BRCA1/2, CHEK2 and RAD...
International audienceA large fraction of the sequence variants of unknown significance or unclassif...
Germline pathogenic variants in BRCA1 confer a high risk of developing breast and ovarian cancer. Th...
International audienceA large fraction of sequence variants of unknown significance (VUS) of the bre...
International audienceA large fraction of sequence variants of unknown significance (VUS) of the bre...
Germline pathogenic variants in BRCA1 confer a high risk of developing breast and ovarian cancer. Th...
International audienceA large fraction of sequence variants of unknown significance (VUS) of the bre...
International audienceA large fraction of sequence variants of unknown significance (VUS) of the bre...
A recent analysis using family history weighting and co-observation classification modeling indicate...
A recent analysis using family history weighting and co-observation classification modeling indicate...
Disruption of the breast cancer susceptibility gene BRCA2 is associated with increased risk of devel...
A recent analysis using family history weighting and co-observation classification modeling indicate...
Paper minigene BRCA2 exons 2-9"Mis-splicing in breast cancer: identification of pathogenic BRCA2 var...
Screening for pathogenic mutations in breast and ovarian cancer genes such as BRCA1/2, CHEK2 and RAD...
A recent analysis using family history weighting and co-observation classification modeling indicate...
Screening for pathogenic mutations in breast and ovarian cancer genes such as BRCA1/2, CHEK2 and RAD...
International audienceA large fraction of the sequence variants of unknown significance or unclassif...
Germline pathogenic variants in BRCA1 confer a high risk of developing breast and ovarian cancer. Th...
International audienceA large fraction of sequence variants of unknown significance (VUS) of the bre...
International audienceA large fraction of sequence variants of unknown significance (VUS) of the bre...
Germline pathogenic variants in BRCA1 confer a high risk of developing breast and ovarian cancer. Th...
International audienceA large fraction of sequence variants of unknown significance (VUS) of the bre...
International audienceA large fraction of sequence variants of unknown significance (VUS) of the bre...
A recent analysis using family history weighting and co-observation classification modeling indicate...
A recent analysis using family history weighting and co-observation classification modeling indicate...
Disruption of the breast cancer susceptibility gene BRCA2 is associated with increased risk of devel...
A recent analysis using family history weighting and co-observation classification modeling indicate...
Paper minigene BRCA2 exons 2-9"Mis-splicing in breast cancer: identification of pathogenic BRCA2 var...
Screening for pathogenic mutations in breast and ovarian cancer genes such as BRCA1/2, CHEK2 and RAD...
A recent analysis using family history weighting and co-observation classification modeling indicate...
Screening for pathogenic mutations in breast and ovarian cancer genes such as BRCA1/2, CHEK2 and RAD...